BioSpace News Archive

KEDPLASMA, a leader in the collection of highquality plasma, is proud to announce a comprehensive remodeling initiative aimed at enhancing the experience of its donors and raising the standard of excellence in its collection centers.

Generate:Biomedicines and Roswell Park Comprehensive Cancer Center announced a strategic collaboration to discover and develop chimeric antigen receptor T-cell therapies, and armoring technologies, for up to three oncology targets, including in ovarian cancer and other solid tumors.

Oculis Holding AG announced that the positive results from Stage 1 of its Phase 3 DIAMOND trial of OCS-01 in patients with diabetic macular edema, will be presented as a late-breaking abstract at the American Academy of Ophthalmology 2023 Annual Meeting, taking place Friday, November 3, 2023 through Monday, November 6, 2023 in San Francisco, California.

United Therapeutics Corporation, a public benefit corporation, announced its financial results for the quarter ended September 30, 2023.

LivaNova PLC, a market-leading medical technology company, reported results for the quarter ended September 30, 2023 and raised full-year 2023 revenue and adjusted diluted earnings per share guidance.

Vapotherm, Inc., announced that it will release financial results for the third quarter of 2023 after the close of trading on Wednesday, November 8, 2023.

Mallinckrodt plc announced that three scientific abstracts evaluating treatment with TERLIVAZ® for injection for adults with hepatorenal syndrome with rapid reduction in kidney function – including its impact on patient care, key HRS endpoints and patient comorbidity – will be presented at the American Society of Nephrology Kidney Week 2023 Scientific Meeting in Philadelphia, Pennsylvania, taking place November 2-5, 2023.

The board of directors of Eli Lilly and Company has declared a dividend for the fourth quarter of 2023 of $1.13 per share on outstanding common stock.

Merck, known as MSD outside of the United States and Canada, announced that Jannie Oosthuizen, president, Human Health U.S., is scheduled to participate in a fireside chat at the UBS BioPharma Conference on Wednesday.

Merck, known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer.